Analysts have recently evaluated Madrigal Pharmaceuticals and provided 12-month price targets. The average target is $497.5, accompanied by a high estimate of $554.00 and a low estimate of $428.00.

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” second-quarter 2025 investor letter ...

Vanderpump Rules' star Scheana Shay is reacting to Peter Madrigal saying that he doesn't like the former members of the show.

Madrigal Pharmaceuticals (NASDAQ:MDGL) has received conditional marketing approval from the European Commission for its liver ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra saw Q2 net sales soar 55% to $212.8M amid strong growth. EU approval expected by ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...

The FDA clearance sets Novo’s medicine up for a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Madrigal's share price rocketed >350% in December last year after positive data from a Phase 3 study of lead drug Resmetirom in NASH. Read more about MDGL here.

Yet the topline results released by Madrigal Pharmaceuticals MDGL 0.70% on Monday looked better than most analysts had expected, sending the stock soaring 220%.